Ophthalmic Pharmaceutical Drugs - A Global Market Perspective

NEW YORK, Jan. 29 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Ophthalmic Pharmaceutical Drugs - A Global Market Perspective

http://www.reportlinker.com/p0164241/Ophthalmic-Pharmaceutical-Drugs---A-Global-Market-Perspective.html

Prevention of blindness has emerged into a top health priority among aging citizens in the developed countries. And increased healthcare spending in these countries is creating a strong demand for advanced ophthalmic therapeutic treatments. This in turn is leading to the rise in investments in ophthalmic drug research, and a parallel spurt in the commercial availability of innovative and promising ocular drugs. Ongoing research studies on developing pharmacologic IOP reducing drugs is expected to lead to the availability of powerful topical drugs with lesser side effects, and higher therapeutic efficacies, thereby overthrowing the present bottleneck of low patient compliance. Pharmacodiversity and newer classes of potent drugs together, are expected to encourage patient compliance, and improve patient outcomes. The market therefore is expected to get a much-awaited respite from the business, and economic repercussions of low patient compliance.

These and other market data and trends are presented in "Ophthalmic Pharmaceutical Drugs: A Global Market Perspective" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

OPHTHALMIC PHARMACEUTICAL DRUGS BMR-1041

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. INDUSTRY OVERVIEW 4

A Curtain Raiser 4

Drugs Developed in the Recent Past 4

What the Future Holds in Store? 5

Where Does the Opportunity Lie? 5

In the Shifting Demographics 5

Which Disease Segment Offers Abundant Opportunities for R&D

Initiatives 6

Leading Companies & Their Areas of Research Interest/Focus 7

Business Opportunities in Ophthalmology: A Fact Sheet 8

Impediments in Picking the Ripe & Low Hanging Opportunities 8

Low Patient Compliance 8

What's the Antidote to Low Patient Compliance? 9

Innovation in Ophthalmic Pharmaceuticals: How Does It Help

Patients? 9

An Unequivocal Discussion About Ocular Drug Design and Delivery 10

Why Understanding of the Metabolic Activity of the Eye is

Important? 10

Pitfalls of Traditional Ocular Treatment 11

Ophthalmic Drug Delivery: A Recapitulation of Facts 12

Antidotes to Low Delivery of Ocular Drugs & High Side Effects 13

Prodrug 14

Soft Drugs (SDs) 14

Soft Corticosteroids 15

Drug Penetration Enhancers 15

Chitosan Based Drugs & Drug Delivery Systems 15

How Chitosan is used to Improve Ocular Drug Retention- On

the Eye's Surface? 16

The Future of Ophthalmic Drug Delivery 17

A Straight Talk About Ophthalmic Drug Delivery Technologies 17

High Flying Expectations of Blistering Pace of Drug

Development- Grounded 17

First Generation Advancements Made in Ocular Drugs 18

Second Generation Advancements Made in Ocular Drugs 19

Limiting Factors 20

3. MARKET DYNAMICS 21

Ophthalmic Pharmaceuticals Poised to Encounter Days of Plenty 21

Ophthalmic Inserts Flaunt the Potential to Eclipse the

Popularity of Eye Drops 21

Rising Incidences of Glaucoma: A Business Case for Ophthalmic

Drugs 22

Aging Population & Environmental Factors Drive Growth 22

Increase in Health Care Spending 23

Opportunities Abound in the Developing Countries 23

Innovative Products Lend Traction to Growth 24

Reimbursements: "Under the Umbrella" 24

4. PRODUCT FACTS 25

5. CORPORATE DEVELOPMENTS 27

Bausch & Lomb Acquires IOL Maker, Eyeonics 27

Akorn Inks Manufacture & Supply Agreement for Ophthalmic Solution 27

CrystalGenomics Enters Into R&D Agreement with Bausch & Lomb 27

Genaera Corporation Quits Evizon Clinical Trials 27

Eyetech Inc Divests Anti-Platelet Derived Growth Factor (PDGF)

Aptamer- Program 27

Amneal, Indoco Agree to Develop & Market Generic Ophthalmic Drugs 28

Bausch & Lomb Acquire Soothe Products from Alimera 28

Froptix, Acuity, eXegenics Merge to Form Opko Corporation 28

Alimera, Emory Collaborate Over Potential Ophthalmic

Treatments Using Novel Antioxidants 28

Santen Signs Agreement with Vistakon Pharmaceuticals for US

Launch of Iquix® 29

Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections 29

QLT Takes Over Forsight Newco II, Inc 29

Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections 29

Novagali Obtains FDA Approval of Nova22007 IND for Ph III Trial 30

Alimera Conducts Phase III Medidur Trial 30

ISTA Pharmaceuticals Files NDA for Xibrom™ QD 30

AzaSite Receives FDA Approval 30

6. MAJOR PLAYERS 31

Akorn, Inc (USA) 31

Alcon Eye Care, Inc (USA) 31

Allergan, Inc. (USA) 31

Alimera Sciences, Inc (USA) 31

Bausch & Lomb, Inc (USA) 31

Genvec, Inc (USA) 32

Glaxosmithkline Plc (UK) 32

Inspire Pharmaceuticals, Inc (USA) 32

Ista Pharmaceuticals, Inc (USA) 32

Merck & Co., Inc (USA) 32

Opko Health, Inc (USA) 33

Otsuka Pharmaceutical Co., Ltd (JAPAN) 33

Pfizer Inc (USA) 33

QLT, Inc. (Canada) 33

Santen Pharmaceutical Co. (Japan) 33

Santen Inc. (US) 33

7. GLOBAL MARKET ANALYTICS 34

8. THE UNITED STATES 42

Emphasis on Greater Awareness About Ophthalmic Disorders 42

Growth Drivers In a Capsule 43

Impediments to Growth 43

Market Fact Sheet 43

Glaucoma Market: A Primer 44

Awareness Among Patients 44

High Costs 45

Treatment Patterns Adopted By Doctors 45

The All Consuming Issue of Compliance 45

Market Share Statistics 46

The New Batting Order 46

Update On Drugs & Their Manufacturers in the US 49

Patent Expirations of Key Ophthalmic Product Brands in the

United States 49

Statistical Findings On Ophthalmic Diseases in the United States 50

9. CANADA 53

Lack of Awareness: A Key Issue 53

10. JAPAN 55

Growth Drivers 55

Market Data Statistics 55

11. EUROPE 57

a. France 61

b. Germany 62

c. The United Kingdom 63

d. Italy 64

e. Spain 65

f. Rest of Europe 68

12. ASIA-PACIFIC 69

13. LATIN AMERICA 70

14. REST OF WORLD 71

EXHIBITS

Table 1: Prevalence of Glaucoma in the World -2006 (In 000

Individuals)

Table 2: Global Ophthalmic Pharmaceutical Drugs Market by

Region for the Period 2007-2015 (Sales in US$ Million)

Table 3: Percentage Breakdown of Global Ophthalmic

Pharmaceutical Drugs Market by Region for the Years 2008 &

2012

Table 4: Global Glaucoma Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 5: Percentage Breakdown of Global Glaucoma Market by

Region for the Years 2008 & 2012

Table 6: Global Anti-allergy Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 7: Percentage Breakdown of Global Anti-allergy Market by

Region for the Years 2008 & 2012

Table 8: Global Anti-infective Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 9: Percentage Breakdown of Global Anti-infective Market

by Region for the Years 2008 & 2012

Table 10: Global Dry Eye Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 11: Percentage Breakdown of Global Dry Eye Market by

Region for the Years 2008 & 2012

Table 12: Global Anti-inflammation Market by Region for the

Period 2007-2015 (Sales in US$ Million)

Table 13: Percentage Breakdown of Global Anti-inflammation

Market by Region for the Years 2008 & 2012

Table 14: Global Back of Eye Market by Region for the Period

2007-2015 (Sales in US$ Million)

Table 15: Percentage Breakdown of Global Back of Eye Market by

Region for the Years 2008 & 2012

Table 16: Global Other Treatment Category Market by Region for

the Period 2007- 2015 (Sales in US$ Million)

Table 17: Percentage Breakdown of Global Other Treatment

Category Market by Region for the Years 2008 & 2012

Table 18: Market Shares of Leading Players in the US Market

for Ophthalmic Pharmaceutical Drugs - 2007E

Table 19: Breakdown of Top 10 Eye/ Lens Care Brands in the US

- 2007

Table 20: Breakdown of Top 5 Eye Care Products in the US -

2007

Table 21: Market Shares of Leading Players in the US

Age-Related Wet Macular Degeneration Market -2006

Table 22: Market Shares of Leading Players in the US Ocular

Allergy Market -2007E

Table 23: Market Shares of Leading Players in the US Market

for Ocular NSAIDs (Topical Non-Steroidal Anti-Inflammatory

Drugs) - 2006

Table 24: Dollar Sales of Major Branded Drugs in the US Market

for Age-Related Macular Degeneration - 2009 & 2012

Table 25: Prevalence of Age-Related Wet Macular Degeneration

in the US - 2009 & 2012

Table 26: Number of Individuals Treated for Wet AMD in the US-

2009 & 2012

Table 27: Prevalence of Ocular Hypertension (OHT) in the US-

2009 & 2011

Table 28: Prevalence of Primary Open Angle Glaucoma (POAG) in

the US - 2009 & 2011

Table 29: Prevalence of Normal Tension Glaucoma (NTG) in the

US - 2009 & 2011

Table 30: Prevalence of Exfoliative Glaucoma (EG) in the

United States for the Years 2009 & 2011 (In Thousand

Individuals)

Table 31: Prevalence of Pigmentary Glaucoma (PG) in the

United States for the Years 2009 & 2011 (In Thousand

Individuals)

Table 32 Breakdown of Number of Individuals Treated for

Glaucoma by Type in the United Sates - 2009 and 2011 (In 000

Individuals)

Table 33: Prevalence of Ocular Allergy in the United States

for the Years 2009 & 2012 (In Millions of Individuals)

Table 34: Number of Individuals Treated for Ocular Allergy in

the United States - 2009 & 2012

Table 35: Prevalence of Cataract in the US - 2009 & 2012

Table 36: Number of Individuals Treated for Cataract With

Ocular NSAIDs (Topical Non-Steroidal Anti-Inflammatory Drugs)

in the US - 2009 & 2012

Table 37: Prevalence of Dry Eye in the US - 2009 & 2012

Table 38: Number of Individuals Treated for Dry Eye in the US

- 2009 & 2012

Table 39: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in the US: 2007-2015 (Sales in US$

Million)

Table 40: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in the US for the Years

2008 & 2012

Table 41: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in Canada: 2007-2015 (Sales in US$

Million)

Table 42: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in Canada for the Years

2008 & 2012

Table 43: Percentage Breakdown of Japanese Market for

Prescription Ophthalmic Drugs by Therapeutic Area - 2005

Table 44: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in Japan: 2007-2015 (Sales in US$

Million)

Table 45: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in Japan for the Years

2008 & 2012

Table 46: Ophthalmic Pharmaceutical Drugs Market by Region in

Europe: 2007-2015 (Sales in US$ Million)

Table 47: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Region in Europe for the Years 2008 & 2012

Table 48: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in Europe: 2007-2015 (Sales in US$

Million)

Table 49: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in Europe for the Years

2008 & 2012

Table 50: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in France: 2007-2015 (Sales in US$

Million)

Table 51: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in France for the Years

2008 & 2012

Table 52: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in Germany: 2007-2015 (Sales in US$

Million)

Table 53: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in Germany for the Years

2008 & 2012

Table 54: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in the UK: 2007-2015 (Sales in US$

Million)

Table 55: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in the UK for the Years

2008 & 2012

Table 56: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in Italy: 2007-2015 (Sales in US$

Million)

Table 57: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in Italy for the Years

2008 & 2012

Table 58: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in Spain: 2007-2015 (Sales in US$

Million)

Table 59: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in Spain for the Years

2008 & 2012

Table 60: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in Rest of Europe: 2007-2015 (Sales in

US$ Million)

Table 61: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in Rest of Europe for

the Years 2008 & 2012

Table 62: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in Asia-Pacific: 2007-2015 (Sales in US$

Million)

Table 63: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in Asia-Pacific for the

Years 2008 & 2012

Table 64: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in Latin America: 2007-2015 (Sales in US$

Million)

Table 65: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in Latin America for the

Years 2008 & 2012

Table 66: Ophthalmic Pharmaceutical Drugs Market by

Therapeutic Category in Rest of World: 2007-2015 (Sales in US$

Million)

Table 67: Percentage Breakdown of Ophthalmic Pharmaceutical

Drugs Market by Therapeutic Category in Rest of World for the

Years 2008 & 2012

COMPANIES PROFILED

To order this report:

Pharmaceutical Industry: Ophthalmic Pharmaceutical Drugs - A Global Market Perspective

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

    
    
    Contact:
    Nicolas Bombourg
    Reportlinker 
    Email: [email protected] 
    US: (805)652-2626 
    Intl: +1 805-652-2626 

SOURCE Reportlinker